Market capitalization | $17.87m |
Enterprise Value | $70.88m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.25 |
P/S ratio (TTM) P/S ratio | 0.57 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 1.63% |
Revenue (TTM) Revenue | $31.47m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
10 Analysts have issued a Marinus Pharmaceuticals Inc forecast:
10 Analysts have issued a Marinus Pharmaceuticals Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 31 31 |
2%
2%
|
|
Gross Profit | 28 28 |
4%
4%
|
|
EBITDA | -122 -122 |
2%
2%
|
EBIT (Operating Income) EBIT | -123 -123 |
2%
2%
|
Net Profit | -140 -140 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
Head office | United States |
CEO | Scott Braunstein |
Employees | 165 |
Founded | 2003 |
Website | www.marinuspharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.